Navigation Links
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Date:3/31/2008

participation in IDENTITY. Because the IDENTITY study also incorporates a "randomized delayed start" design, even those subjects initially assigned to the placebo arm of the study will be started on active LY450139 treatment sometime before the end of the 21-month study period. Both the subjects and investigators will be blinded to the exact timing of this delayed start of study drug administration.

"Alzheimer's is a devastating disease that destroys brain cells, affecting everything from a patient's memory to their work and social life. Currently available medications treat the symptoms of Alzheimer's disease but have not been shown to change its underlying progression, creating an urgent unmet medical need. Today, we are proud to announce the start of the IDENTITY clinical trial and hold hope that LY450139 will represent an advance in the attempt to slow the progression of this fatal disease. We encourage patients or their caregivers to review the enrollment criteria for IDENTITY to see if they are eligible to participate," said Eric Siemers M.D., Medical Director, Alzheimer's disease research for Eli Lilly and Company.

Alzheimer's disease is a progressive neurodegenerative condition that is the most common cause of dementia in patients over 65 years of age. Estimates show that 6-8% of people over age 65 are affected by Alzheimer's disease(1), totaling approximately 5 million people in the United States alone(2). Every 72 seconds, an American is developing Alzheimer's disease(3), and it is the seventh-leading cause of death in the United States(4). The direct and indirect health care costs associated with Alzheimer's disease in the U.S. are estimated to be about $150 billion(5). In 2005, the total cost worldwide was estimated at $315.4 billion(6).

Given the aging population, without the availability of medicines that delay or prevent the onset of Alzheimer's disease, the number of affected people is expected to at least triple by the year 2050
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
2. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
3. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
4. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
5. Lilly Receives NCQA Design Certification for Depression Care Management Program
6. Lilly and Glenmark Pharmaceuticals Announce License Agreement
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
9. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
10. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
11. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Calif. , Aug. 27, 2014  After the ... and Personal Injury billing solution for medical practices ... positive response toward the new software. "The ... Sandy Thompson . "The sheer number of demos ... true the need was for these types of software ...
(Date:8/27/2014)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global ... participating in the Morgan Stanley 2014 Global Healthcare Conference ... New York , on Tuesday, September 9, 2014.  ... will be presenting at 9:10 a.m. Eastern Time.  ... join Mr. Dvorak for the Q&A session. ...
(Date:8/27/2014)... 2014 Sinovac Biotech Ltd. (NASDAQ: SVA ), ... , today announced the results of the Company,s 2014 Annual General ... Beijing , PRC. The required quorum, a majority of ... The Company,s shareholders approved the following proposals:  , The ... Simon Anderson , Kenneth Lee and Meng ...
Breaking Medicine Technology:Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2
... 2011 Ingenious Med, the leading platform for automated ... now available on the App Store for iPhone, iPod ... part of the company,s presence at the Hospital Information ... Ingenious Med,s 9,000 users to access the charge and ...
... Feb. 17, 2011 NexBio, Inc. announced the presentation ... a Patient after Allogeneic Stem Cell Transplantation" at the ... February 17-21 in Honolulu, Hawaii.  The data was presented ... General Hospital and Harvard Medical School. Parainfluenza ...
Cached Medicine Technology:HIMSS11: Ingenious Med Launches Billing and Data Capture App for iPhone, iPod touch and iPad 2NexBio’s DAS181 (Fludase®*) Improved Symptoms in a Severely Immunocompromised Patient with Parainfluenza Pneumonitis 2NexBio’s DAS181 (Fludase®*) Improved Symptoms in a Severely Immunocompromised Patient with Parainfluenza Pneumonitis 3
(Date:8/27/2014)... Aspirus Wausau Hospital today announced the first ... Digital O.R. at Aspirus Wausau Hospital, in Wausau, WI. ... rooms will be Buzz, a centralized surgical hub for ... planning, navigation, imaging and communications connectivity. , Buzz ... and hardware all controlled from the full HD 42” ...
(Date:8/27/2014)... UNIWIGS, one of the leading purveyors of real and synthetic ... sales on all its products, for the coming Labor Day. , ... UniWigs hair products in two ways: when they spend ... a coupon code LABOR10; while when they spend more than $299, ... deal which coupon code is needed when securely checkout, there are ...
(Date:8/27/2014)... Hepatocellular carcinoma (HCC) is the second leading cause ... are due to the difficulty in treating this ... epirubicin, cisplatin, 5-fluorouracil, etoposide or combinations therein. This ... are not able to reach in a sufficient ... that are not harmful to the rest of ...
(Date:8/27/2014)... Fluorochemicals are synthetically produced chemicals, which repel water ... and chemical conditions in industrial processing. These characteristics ... and products, such as coatings for food paper ... that they are difficult to break down and ... fluorochemicals have known correlations with harmful health effects, ...
(Date:8/27/2014)... 27, 2014 DISCcert has scheduled its ... place Sept 10th, 17th, 24th, and Oct 1st from ... receive a certification seal that will allow them to ... consists of four weekly one-hour webinar sessions. In between ... are offered individual coaching time. , Trainers, participating ...
Breaking Medicine News(10 mins):Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:UniWigs Is Offering A Big Sale for Labor Day on All Its Products 2Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 2Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 3Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 3Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 2Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 3Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 4
... researcher Dr. Daniel Von Hoff, a member of ... in-depth look at the "lost opportunity" in phase ... companies use the phase I trial to evaluate ... advocates that it can also provide valuable efficacy ...
... have made several, subtle changes in the structure of a ... according to a study published in a December edition of ... have profound implications for the treatment of hemophilia, the inherited ... Americans. , In most cases, hemophilia is ...
... those with lupus, rheumatoid arthritis , , MONDAY, Dec. 22 ... cells, but these cells stay in an "off" state, ... the body cause autoimmune diseases such as lupus and ... adults are true precursors of the self-attacking immune cells ...
... common this time of year , , MONDAY, Dec. 22 ... holidays this year, with many people both blue and ... jobless rate in three decades and a jackknifing stock market. ... often during the winter months not only because of the ...
... fresh start for career-building in today,s tough economic times. The ... professions. , ... (PRWEB) December 22, ... a recruiting campaign targeting career changers and other potential students. ...
... 2008, Cambridge, UK Scientists report that human gene mutations ... Disease, a fatal nervous system disorder that begins during childhood. ... (DMM), dmm.biologists.org , describes how the extent of ... in humans. ,The initial, milder symptoms of Batten ...
Cached Medicine News:Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 2Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 3Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 4Health News:Redesigned protein accelerates blood clotting 2Health News:Redesigned protein accelerates blood clotting 3Health News:Redesigned protein accelerates blood clotting 4Health News:Blue and Broke for the Holidays 2Health News:Blue and Broke for the Holidays 3Health News:Blue and Broke for the Holidays 4Health News:Parker College of Chiropractic Education Launches Recruiting Campaign for Career Changers and Potential Students 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: